FDA approves Humira for treatment of noninfectious intermediate, posterior and panuveitis

The FDA has approved Humira for the treatment of noninfectious intermediate and posterior uveitis and panuveitis, according to a press release from AbbVie. With this approval, the company now has 10 approved indications for Humira (adalimumab) in the U.S. for immune-mediated diseases.